Trialists should focus less on physician-defined outcomes and more on what matters to patients, Mario Gaudino says.

Bernard Prendergast and Jordan Strom discuss the evolution of AS referral and how earlier treatment impacts patient outcomes.

The early impact of gestational diabetes, hypertensive disorders of pregnancy, and obesity appears to grow as kids age.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

The findings highlight the importance of rheumatology, cardiology, and primary care working together to intervene early.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

This can be an important add-on to echocardiography in patients with a borderline need for intervention, researchers say.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...